It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?
The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Related articles
- Scotland Yard is set to pay a large sum of money to a French publisher arrested by counter-terror of2024-05-01
- Donald Trump Jr has claimed that Sean 'Diddy' Combs' late long-term girlfriend Kim Porter was afraid2024-05-01
Wealthy residents are fleeing LA, San Francisco and Orange County to little
Affordable real estate in Cali city hotspots is hard to come by - so much so that wealthy citizens a2024-05-01- An all-girls football team has won a boys' league after going unbeaten all season and earning the 'i2024-05-01
Judge clears former Kentucky secretary of state Alison Lundergan Grimes of ethics charges
FRANKFORT, Ky. (AP) — Former Kentucky Secretary of State Alison Lundergan Grimes has been cleared of2024-05-01South Dakota man sentenced to nearly 90 years in prison for his baby son's 2021 death
SIOUX FALLS, S.D. (AP) — A South Dakota judge on Friday sentenced a Sioux Falls man to nearly 90 yea2024-05-01
atest comment